Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Trillium Therapeutic NASDAQ: TRIL-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 9.41
Day High 9.97
Open:9.47
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (`do not eat`) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (`eat`) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Strong Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders
- GlobeNewswire - Wed Jun 9, 6:00AM CDT
GlobeNewswire - CMTX
Wed Jun 9, 6:00AM CDT
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the "Corporation"), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 8, 2021.
Novel Anti-Cancer Drugs Permeate the Marketplace
- PR Newswire - PRF - Tue May 25, 8:00AM CDT
PR Newswire - PRF - CMTX
Tue May 25, 8:00AM CDT
, /PRNewswire/ -- The cancer therapeutics market is one of the largest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with cancer in in 2020 alone. However, the oncology and cancer drug market is expected to grow largely due to the surge in cancer research, the rise in the geriatric population worldwide, as well as the increase in collaboration between pharmaceutical companies. Moreover, the high market growth potential in developing nations, a rise in the number of pipeline products, and an upsurge in demand for personalized medicines are expected to create new opportunities for market players. And, according to data published by Market Industry Reports, the cancer therapeutics market was estimated to be valued at over in 2019 and is anticipated to grow at a CAGR of ~7.7% from 2019 to 2030. Sunshine Biopharma Inc. (OTC: SBFM), Verastem, Inc. (NASDAQ: VSTM), Trillium Therapeutics Inc. (NASDAQ: TRIL), ImmunoGen, Inc. (NASDAQ: IMGN), Sorrento Therapeutics, Inc. (NASDAQ: SRNE).
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
- PR Newswire - PRF - Thu May 20, 7:45AM CDT
PR Newswire - PRF - CMTX
Thu May 20, 7:45AM CDT
PALM BEACH,  Fla., /PRNewswire/ -- Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so will money flow into R&D efforts to treat this condition. Pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S.  Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.  The global pancreatic cancer treatment market is to reach in 2025, according to a new report by Grand View Research, Inc.  Active biotech and pharma companies in the markets this week include (NASDAQ: ONCY) (TSX: ONC), (NASDAQ: ATNX),  (NASDAQ: SEEL), (NASDAQ: TRIL ) (TSX: TRIL), (NASDAQ: MRKR).
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 7.47 +33.02% increase
on 05/25/21
Period Open:8.78
Price movement based on the high, low and last over the given period.
10.34 -3.97% decrease
on 06/09/21
+1.15 (+13.10%) increase
since 05/17/21
3-Month 7.47 +33.02% increase
on 05/25/21
Period Open:11.00
Price movement based on the high, low and last over the given period.
11.50 -13.65% decrease
on 04/01/21
-1.07 (-9.73%) decrease
since 03/17/21
52-Week 5.75 +72.70% increase
on 07/30/20
Period Open:7.90
Price movement based on the high, low and last over the given period.
20.96 -52.62% decrease
on 11/30/20
+2.03 (+25.70%) increase
since 06/17/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies